Therapeutic targeting of downstream LT-associated synthases might be a more direct approach to steer the direction of LM biosynthesis towards more beneficial LMs during specific MS disease stages and targeting of the LTB4 receptor 1 (BLT1) may provide such a tool. The gene discussed is LTB4R; the disease is myeloid sarcoma.